Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG-110 in Healthy Volunteers with Skin Wounds
NCT03603431Phase 1Completed
- Sponsor
- Viridian Therapeutics
- Start
- Apr 2018
- Primary completion
- Mar 2019
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MRG-110 in wound (4 arms), sponsored by Viridian Therapeutics. Primary endpoint: Number of participants with treatment-related adverse events. Started Apr 2018; status: completed.
02
Drugs
MRG-110
03
Conditions
wound
Beyond the preview
Go deeper on NCT03603431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03603431.